Travere Therapeutics shares are trading higher after the company announced it that the FDA has granted full approval to FILSPARI to slow kidney function decline in adults with primary IgAN who are at risk of disease progression. Also, HC Wainwright & Co maintained a Buy rating on the stock and raised its price target from $20 to $23.
Portfolio Pulse from Benzinga Newsdesk
Travere Therapeutics' shares rose following FDA's full approval of FILSPARI for treating primary IgAN. HC Wainwright & Co also maintained a Buy rating and increased the price target from $20 to $23.
September 06, 2024 | 11:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Travere Therapeutics' stock is up due to FDA's full approval of FILSPARI for primary IgAN, and HC Wainwright & Co's increased price target to $23.
The FDA's full approval of FILSPARI is a significant milestone for Travere Therapeutics, likely boosting investor confidence and stock value. Additionally, HC Wainwright & Co's maintained Buy rating and increased price target further support a positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100